SCHEMBL4139475

SCHEMBL4139475

C[C@@H]1CN([C@H](c2ccccc2)c2ccccc2F)CCN1CC(=O)O

nearest known ligand 0.77

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SLC6A9 P48067 14/20 0.77
▸ OPRM1 P35372 1/20 0.46
▸ OPRD1 P41143 1/20 0.46
▸ OPRK1 P41145 1/20 0.46
▸ OPRL1 P41146 1/20 0.46
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ CACNA2D1 P54289 1/20 0.41
▸ CACNA1B Q00975 1/20 0.41
▸ CACNB1 Q02641 1/20 0.41
▸ CACNA1C Q13936 1/20 0.41
▸ CHRM1 P11229 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4139479 1.00 SLC6A9 (0.77) SLC6A9OPRM1OPRD1OPRK1OPRL1
SCHEMBL4148340 1.00 SLC6A9 (0.77) SLC6A9OPRM1OPRD1OPRK1OPRL1
SCHEMBL4148347 1.00 SLC6A9 (0.77) SLC6A9OPRM1OPRD1OPRK1OPRL1
SCHEMBL4139483 1.00 SLC6A9 (0.77) SLC6A9OPRM1OPRD1OPRK1OPRL1
SCHEMBL4144936 0.89 SLC6A9 (0.71) SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL4144939 0.89 SLC6A9 (0.71) SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL4148051 0.89 SLC6A9 (0.71) SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL4144932 0.89 SLC6A9 (0.71) SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL4148054 0.89 SLC6A9 (0.71) SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL4157393 0.88 SLC6A9 (1.00) SLC6A9MEN1KMT2ACACNA2D1CACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735383-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2014-05-27 — — US claimed
EP-2041088-B1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC (US) 2014-01-08 — — EP claimed
US-20120195985-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2012-08-02 — — US claimed
US-20090227595-A1 GLYCINE TRANSPORTER-1 INHIBITORS HITCHCOCK STEPHEN 2009-09-10 — — US claimed
CN-101479243-A Glycine transporter-1 inhibitors AMGEN INC (US) 2009-07-08 — — CN claimed
US-7538114-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2009-05-26 — — US claimed
US-20080004289-A1 Glycine transporter-1 inhibitors AMGEN INC. 2008-01-03 — — US claimed
US-9663476-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2017-05-30 — — US disclosed
EP-2947067-A1 Glycine transporter-1 inhibitors Amgen, Inc (US) 2015-11-25 — — EP disclosed
US-20150307457-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2015-10-29 — — US disclosed
US-8735383-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2014-05-27 — — US disclosed
EP-2041088-B1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC (US) 2014-01-08 — — EP disclosed
EP-2565183-A1 Glycine transporter-1 inhibitors Amgen Inc. (US) 2013-03-06 — — EP disclosed
CN-101479243-B Glycine transporter-1 inhibitors AMGEN INC 2013-01-02 — — CN disclosed
US-20120195985-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2012-08-02 — — US disclosed
US-8183244-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2012-05-22 — — US disclosed
US-20090227595-A1 GLYCINE TRANSPORTER-1 INHIBITORS HITCHCOCK STEPHEN 2009-09-10 — — US disclosed
CN-101479243-A Glycine transporter-1 inhibitors AMGEN INC (US) 2009-07-08 — — CN disclosed
US-7538114-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2009-05-26 — — US disclosed
US-20080004289-A1 Glycine transporter-1 inhibitors AMGEN INC. 2008-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227595-A1 GLYCINE TRANSPORTER-1 INHIBITORS SLC18A2, SLC7A11, SLC6A5 SLC6A9 8/4885OPRM1 1216/4885OPRD1 2137/4885
US-20120195985-A1 GLYCINE TRANSPORTER-1 INHIBITORS SLC18A2, SLC6A5, SLC1A2 SLC6A9 6/4885OPRM1 1113/4885OPRD1 2031/4885
US-20080004289-A1 Glycine transporter-1 inhibitors SLC18A2, SLC7A11, SLC6A5 SLC6A9 8/4885OPRM1 1216/4885OPRD1 2137/4885
US-20150307457-A1 GLYCINE TRANSPORTER-1 INHIBITORS SLC18A2, SLC7A11, SLC6A5 SLC6A9 8/4885OPRM1 1216/4885OPRD1 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback